

# Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC

NCT06137274

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	H. Lee Moffitt Cancer Center and Research Institute
<b>Enrollment</b>	35 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- ECOG performance status of 0, 1
- Patients with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or unknown primary in the neck.
- Patients with measurable disease, either at primary site or neck per RECIST 1.1.

... and 3 more (see full listing online)

### Exclusion (5)

- Pregnancy or lactation
- Patients who have had prior radiotherapy to the head and neck or prior systemic therapy for the index cancer.
- Patients who had undergone definitive surgery for the index cancer.
- Patients with distant metastatic disease
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.

## Locations (1 total)

---

Moffitt Cancer Center, Tampa, Florida, United States